1. Typical Challenges in the Replacement of Classical Heterocycles

1.1 Why Piperidine, Piperazine, and Morpholine Have Long Been Used Frequently

In small-molecule drug design, saturated heterocycles such as piperidine, piperazine, morpholine, and tetrahydropyran are frequently used because they are structurally stable, their synthetic routes are well established, commercial building blocks are widely available, and they can provide basic centers, hydrogen-bond acceptors, solubility modulation, and substituent attachment points.

However, these advantages do not mean that they can always meet the needs of late-stage optimization. When a project requires further improvement in selectivity, reduction of off-target risk, conformational modification, adjustment of substituent orientation, or structural differentiation, classical heterocycles may encounter the following limitations:

In medicinal chemistry, “ring replacement” is intended to answer a more specific question: when the original heterocycle can no longer further improve selectivity, physicochemical properties, metabolic stability, or structural differentiation, can a three-dimensional rigid scaffold be used to reorganize how the molecule contacts the target?

1.2 The Core Task of Bioisosteric Replacement: Retaining Key Interactions While Directionally Optimizing Molecular Properties

The purpose of bioisosteric replacement is to directionally optimize physicochemical properties, spatial shape, and the mode of target interaction while retaining the key functions of the original pharmacophore.

In drug molecules, a classical heterocycle often performs multiple functions simultaneously. For example, piperazine may provide a bis-nitrogen polar center and linker function; morpholine may modulate solubility and hydrogen-bond acceptor capacity; and piperidine may provide aliphatic amine character and hydrophobic volume. Therefore, when replacing these heterocycles, the first step is to determine which functions must be retained.

At the same time, replacement also needs to address the shortcomings introduced by the original structure. For example, the original heterocycle may have excessive conformational flexibility, suboptimal substituent orientation, overly strong basicity, unsuitable lipophilicity, insufficient metabolic stability, or limited structural differentiation. The value of heterospirocycles lies precisely in retaining key interactions while using a more rigid three-dimensional scaffold and more defined exit vectors to reorganize the spatial contacts between the molecule and the target.

2. Design Logic of Heterospirocycles: Ring Strain, Heteroatoms, and Exit Vectors

2.1 Ring Strain: Using Rigidity to Reduce Unproductive Conformations

Both spiro[3.3]heptane and spiro[2.3]hexane contain small-ring structures. Small rings restrict bond angles and conformational changes, making free rotation more difficult. For drug molecules, this restriction may become a design advantage in an appropriate target environment.

If a flexible fragment must pay a high conformational reorganization cost before binding to the target, a rigid scaffold may reduce the proportion of unproductive conformations and bring the molecule closer to the shape required for binding. By sharing a spiro atom, spirocyclic structures fix two rings in an approximately orthogonal spatial relationship, thereby increasing three-dimensionality and conformational definition.

This is also a concrete manifestation of the “escape from flatland” concept in heterocycle replacement: increasing the fraction of sp³-hybridized carbons (Fsp³) and three-dimensional structural features is commonly used to explore richer chemical space and may improve solubility, shape complementarity, and target fit.

2.2 Heteroatoms: Modulating Interactions and Physicochemical Properties

Nitrogen, oxygen, sulfur, sulfoximine, and other functional groups in heterospirocycles play important roles.

2.3 Exit Vectors: Heterospirocycles Change the Direction of Substituent Projection

An exit vector refers to the spatial direction in which a substituent projects from the core scaffold. The key value of heterospirocycles lies in the fact that the two small rings connected by the spiro atom usually form a more defined three-dimensional architecture, allowing substituents to extend in different directions. Compared with traditional piperidine, piperazine, and morpholine, heterospirocycles can provide more constrained and more designable exit vectors.

The core question for a heterospirocycle is whether it allows medicinal chemists to more precisely control:

① which atom retains the key interaction;

② which substituent enters the target pocket;

③ which direction is exposed to solvent;

④ which position is used for subsequent SAR expansion.

The replacement relationships between classical six-membered heterocycles and representative heterospirocycles are shown in the figure below:

3. Spiro[3.3]heptane: A Mature Replacement Logic for Classical Six-Membered Heterocycles

Representative core scaffolds of spiro[3.3]heptane are shown in the figure below:

3.1 2,6-Diazaspiro[3.3]heptane: A Representative Scaffold for Piperazine Replacement

2,6-Diazaspiro[3.3]heptane is a representative three-dimensional bioisostere of piperazine. It retains two nitrogen atoms, but changes the spatial relationship between the two nitrogen atoms and the substituent exit directions by having two azetidine rings share a spiro atom. The medicinal chemistry significance of this type of replacement mainly lies in three aspects:

In studies modifying Olaparib-related PARP inhibitor scaffolds, researchers used 2,6-diazaspiro[3.3]heptane as a piperazine replacement and observed improved target selectivity and reduced off-mechanism cytotoxicity. This case shows that heterospirocycle replacement may not only change physicochemical properties, but also affect target selectivity and off-target risk.

3.2 2-Oxa-6-azaspiro[3.3]heptane: A Typical Case of Morpholine Replacement

Morpholine is commonly used to modulate aqueous solubility, polarity, and hydrogen-bond acceptor capacity. 2-Oxa-6-azaspiro[3.3]heptane retains the N/O combination, but transforms the six-membered ring into a three-dimensional structure composed of two four-membered rings. The key differences between this replacement and morpholine are reflected in three aspects:

This type of scaffold is suitable for the following situation: when morpholine in the original molecule mainly contributes to solubility and polarity modulation, but conventional morpholine can no longer further improve selectivity, metabolic properties, or spatial fit, 2-oxa-6-azaspiro[3.3]heptane may be considered for replacement screening.

3.3 2-Azaspiro[3.3]heptane and 1-Azaspiro[3.3]heptane: Different Solutions for Piperidine Replacement

Piperidine is a very common aliphatic amine ring in small-molecule drugs. Both 2-azaspiro[3.3]heptane and 1-azaspiro[3.3]heptane can serve as piperidine replacement scaffolds, but their design logic is not entirely the same.

2-Azaspiro[3.3]heptane compresses the flexible six-membered ring of piperidine into a spirocyclic system, thereby retaining aliphatic amine character while changing the spatial shape. 1-Azaspiro[3.3]heptane further changes the position of the nitrogen atom, allowing it in some cases to display basicity, solubility, lipophilicity, and metabolic stability characteristics different from those of the 2-aza isomer.

This indicates that even when the molecular formula and scaffold type are similar, different nitrogen atom positions may lead to completely different medicinal chemistry outcomes. Therefore, in actual projects, it is necessary to further evaluate:

① whether the nitrogen atom still performs the original salt-forming or target-interaction role;

② whether the substituent after replacement can still enter the original binding pocket;

③ whether basicity and lipophilicity change in the direction required by the project;

④ whether the synthetic route supports rapid preparation of substituted analogues.

3.4 1-Oxaspiro[3.3]heptane: A Spatial Compression Strategy for Tetrahydropyran Replacement

Tetrahydropyran can provide an ether oxygen, hydrophobic volume, and relatively mild polarity modulation. 1-Oxaspiro[3.3]heptane can be regarded as a more compact and more rigid potential replacement for some tetrahydropyran motifs, especially 3-substituted tetrahydropyrans.

The focus of this type of replacement is to:

① retain the hydrogen-bond acceptor capacity provided by the ether oxygen;

② compress the ring conformation;

③ change the spatial distribution of hydrophobic volume;

④ provide new positions for functional-group transformation.

Because the medicinal chemistry applications and synthetic methods of this scaffold are still less mature than those of morpholine and piperazine replacement scaffolds, it is more suitable for small-scale, hypothesis-driven replacement screening rather than as a general-purpose tetrahydropyran replacement.

4. Spiro[2.3]hexane: A Highly Strained Small-Ring Scaffold and New Three-Dimensional Replacement Space

Representative core scaffolds of spiro[2.3]hexane are shown in the figure below:

4.1 Structural Features of Spiro[2.3]hexane: High Strain and Compact Three-Dimensional Architecture Introduced by a Three-Membered Ring

Spiro[2.3]hexane consists of a three-membered ring and a four-membered ring sharing one spiro atom. Compared with spiro[3.3]heptane, which is composed of two four-membered rings, the spiro[2.3]hexane scaffold is smaller and usually has higher ring strain and a more compact three-dimensional architecture. Because scalable synthetic routes, commercial building blocks, and medicinal chemistry application cases for this class of scaffolds are relatively limited, their replacement value is still being further explored.

This also gives spiro[2.3]hexane scaffolds a relatively higher barrier to application. Their smaller scaffold size and more pronounced ring strain mean that the construction and functionalization of related heteroatom-containing derivatives depend more heavily on controllable, selective, and scalable synthetic routes.

Spiro[2.3]hexane is more suitable in the following situations:

① the classical six-membered ring is too large or too flexible;

② stronger conformational restriction is required;

③ the substituent projection angle needs to be changed;

④ the project requires clear structural differentiation.

4.2 1-Oxaspiro[2.3]hexane: A Highly Strained Intermediate and Entry Point for Derivatization

1-Oxaspiro[2.3]hexane contains oxirane and cyclobutane structures and can serve as a highly strained synthetic intermediate. Its importance lies in the fact that it can be converted into more complex drug-like structures through ring opening, ring expansion, cross-coupling, and related transformations.

This type of scaffold is suitable for constructing specially substituted cyclobutanols, cyclopentanones, or other structures that are difficult to obtain through conventional routes. Its value is more oriented toward serving as a “synthetic entry point”: using strain release to drive reactions and using the small ring as a starting point for subsequent functionalization.

4.3 5-Azaspiro[2.3]hexane and 4-Azaspiro[2.3]hexane: Conformationally Constrained Candidate Bioisosteres of Piperidine

5-Azaspiro[2.3]hexane is composed of an azetidine and a cyclopropane ring, and is one of the more closely watched spiro[2.3]hexane scaffolds for piperidine replacement. It retains aliphatic amine character, but is more compact and more rigid than piperidine, and its substituent directions are also clearly different.

4-Azaspiro[2.3]hexane is its constitutional isomer. Preliminary physicochemical studies have shown that replacing piperidine with 4-azaspiro[2.3]hexane may reduce the basicity of the parent compound and increase or alter lipophilicity; its 1,4-disubstituted scaffold has exit vectors similar to those of trans-1,4-disubstituted cyclohexane and 1,4-disubstituted piperidine.

These studies lead to a practical conclusion: when the project goal is to modulate the basicity, conformation, and substituent direction of a piperidine fragment, 4-aza- or 5-azaspiro[2.3]hexane is worth evaluating as part of a small-scale replacement set.

4.4 4,5-Diazaspiro[2.3]hexane: Multi-Heteroatom Scaffolds Opening New Chemical Space

4,5-Diazaspiro[2.3]hexane represents a more frontier-oriented direction: introducing two heteroatoms into a smaller spirocycle.

Its medicinal chemistry potential has not yet become as mature as that of piperazine or morpholine replacements, but its value lies in providing new geometric constraints, dipole-moment distributions, and functionalization positions. For future research on heterospirocycles, multi-heteroatom spirocycles offer a way to more precisely tune molecular shape, polarity, and exit vectors.

5. How to Select Heterospirocycles in Medicinal Chemistry Projects

5.1 Step One: Define the Heterocycle to Be Replaced

Different heterocycles perform different functions, and the corresponding choices of heterospirocycles are also different.

5.2 Step Two: Distinguish the Properties That Need to Be Retained from Those Intended for Optimization

If a heterospirocycle only introduces a “different structure” but does not clearly solve a problem related to physicochemical properties, selectivity, or synthetic expansion, then it should not be prioritized.

5.3 Step Three: Use Exit Vectors to Judge Whether the Replacement Is Reasonable

One of the most easily overlooked issues in drug molecule optimization is whether the substituent still points in the correct direction after replacement.

Before performing heterospirocycle replacement, the following questions should be prioritized:

① Does the substituent on the original heterocycle form a key interaction with the target?

② Does the direction of the substituent after replacement deviate from the original binding site?

③ Can the new exit vector enter an unused hydrophobic pocket or polar region?

④ Can the direction of the heteroatom still retain key hydrogen-bonding or electrostatic interactions?

⑤ Does the replacement introduce new clashes, distortions, or unfavorable exposure?

If structural biology data are unavailable, replacement priorities can also be preliminarily assessed through low-energy conformer alignment, three-dimensional shape comparison, dipole-moment analysis, and computer-assisted clustering, also known as in silico clustering.

It should be emphasized that heterospirocycle replacement is not a universal gain strategy. Its effect depends on the true role of the original heterocycle in the molecule, changes in pKa/logD/TPSA after replacement, whether the exit vectors match the binding pocket, whether new synthetic bottlenecks are introduced, and whether small-ring strain affects chemical stability and scale-up safety.

6. From Synthesis to Application: Medicinal Chemistry Requirements for Heterospirocycle Route Design

For drug discovery, a truly valuable synthetic route should meet at least four conditions:

From this perspective, valuable synthetic advances in recent years have mainly focused on the following directions:

① rapid construction of highly strained cores through [2+2] cycloaddition;

② strain-release functionalization using bicyclo[1.1.0]butane (BCB) or azabicyclo[1.1.0]butane (ABB);

③ introduction of complex substituents through photochemical, radical, or metal-catalyzed reactions;

④ development of enantioselective routes to avoid late-stage resolution;

⑤ use of flow chemistry to improve safety, scalability, and reaction consistency.

The common goal of these methods is to make heterospirocycles into building blocks that can be practically used in medicinal chemistry projects. Whether these routes are suitable for a specific project still requires simultaneous evaluation of raw material availability, scale-up safety, functional-group tolerance, and isomer control.

7. Building Blocks and Synthetic Raw Materials Related to Spiro[3.3]heptane and Spiro[2.3]hexane

Table 1. Reference Compounds of Classical Six-Membered Heterocycles

Table 2. Key Raw Materials for Heterospirocycle Synthesis

Table 3. Spiro[3.3]heptane Cores and Functionalized Building Blocks

Table 4. Spiro[2.3]hexane Cores and Protected Building Blocks

Note: The above products are representative Aladdin products for scientific research and formulation research. For more information on product specifications, grades, and COA details, please search by “product name/CAS/catalog number” on the Aladdin official website.

For more related articles, please see below:

Spirocyclic Building Blocks for Scaffold Assembly

Innovations in the design of stereospecific drug molecular structures: Spirocyclic Scaffolds

Cyclic isomers--Azabicyclic molecular building blocks to aid drug design

One Atom Can Change a Drug’s Fate: Atom-Level Knobs and a Functional-Group Toolbox for Medicinal Chemistry (Methyl / Halogen Bonding / 3D Building Blocks / Late-Stage Fluorination + Product-Selection Tables)

The Role of 7-Membered Nitrogen Heterocycles in Drug Discovery: Microstate Management, Conformational Bias, and Developability Trade-offs (with Research Selection Navigator and Product Tables 1–3)

Pyridinones as “Property Knobs” in Drug Design: From Tautomers and H-Bonding Fingerprints to Product Selection (Tables A–C)

Piperazine Selection Guide: Using a “Six-Membered Diaza Ring” to Make Salt Forms and Linking Strategies More Controllable (Appendix Tables 1–4 Product Navigator)

Why Do We So Often Add a “Morpholine Ring” to Molecules? — Definitions, Structural Features, and a Selection Guide to Morpholine/Thiomorpholine (with Tables 1–4)

Piperidine and Its Derivatives: Controllable Design of Charge, Conformation, and Connecting Exit with Product Navigation (Tables 1–5)

Pyran and the “Pyran Family” Research Selection Guide: Key Structural Points, a Classification Roadmap, and Experimental Selection Navigation